Bayer has acquired BlueRock Therapeutics in a deal valued at $600 million that will give the drugmaker a platform to research and develop new stem cell therapies.
The German drugmaker helped set up the Cambridge, MA-based Bluerock as part of a joint venture with Versant Ventures three years ago. BlueRock Therapeutics is focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary induced pluripotent stem cell (iPSC) platform.
With this transaction, Bayer will own full rights to BlueRock's CELL+GENETM platform, including a broad intellectual property portfolio and associated technology platform including iPSC technology, gene engineering and cell differentiation capabilities
Bayer will acquire the remaining stake for approximately $240 million in cash to be paid upfront at closing and an additional $360 million payable upon achievement of pre-defined development milestones. With Bayer currently holding 40.8 percent stake, the investment corresponds to a total company value of BlueRock Therapeutics of approximately $1 billion. The deal, subject to regulatory approval, is expected to close in the third quarter of 2019.
Read the press release
Don't miss your Daily Dose. Get news like this delivered right to your inbox.